Center for Value-Based Insurance Design University of Michigan, Ann Arbor
J Manag Care Spec Pharm. 2019 Sep;25(9):1026-1027. doi: 10.18553/jmcp.2019.25.9.1026.
No outside funding supported the writing of this letter. Fendrick discloses consulting relationships with AbbVie, Amgen, Centivo, Community Oncology Association, Department of Defense, EmblemHealth, Exact Sciences, Freedman Health, Health at Scale Technologies, Health Management Associates, Lilly, MedZed, Penguin Pay, Risalto, Sempre Health, State of Minnesota, Wellth, and Zansors and also discloses a research relationship with AHRQ, Boehringer-Ingelheim, Gary and Mary West Health Policy Center, Laura & John Arnold Foundation, National Pharmaceutical Council, PCORI, PhRMA, RWJ Foundation, and State of Michigan/CMS. Shrosbree has nothing to disclose.
本信函的撰写没有接受任何外部资金支持。芬德雷克披露了与 AbbVie、安进、Centivo、社区肿瘤学会、国防部、EmblemHealth、Exact Sciences、Freedman Health、Health at Scale Technologies、Health Management Associates、礼来、MedZed、Penguin Pay、Risalto、Sempre Health、明尼苏达州、Wellth 和 Zansors 的咨询关系，并披露了与 AHRQ、勃林格殷格翰、加里和玛丽·韦斯特健康政策中心、劳拉和约翰·阿诺德基金会、国家药品理事会、PCORI、PhRMA、RWJ 基金会以及密歇根州/CMS 的研究关系。Shrosbree 没有需要披露的事项。
